Endocrine Abstracts

Even in the presence of normally circulating androgens, the imbalance between estrogen and androgen in males between the prepubertal and pubertal periods may have an impact on male reproductive function. While there are many variables that affect how each person reaches puberty at different times, boys who are becoming more obese have higher aromatase activity. This enzyme turns testosterone into estradiol permanently, which lowers testosterone levels and raises estrogen levels. It has been observed that aromatase inhibitors enhance boys’ pubertal condition and increase height prediction in boys of short stature. The study aims to establish the safety and efficacy of aromatase inhibitors in pediatric male patients with hypoestrogenic hypogonadism, as well as the relevance of analysis in interpreting the rise in obesity and the advantages of treatment among children. A retrospective investigation was carried out on guys between the ages of 12 and 17 who were in the process of puberty and had a confirmed diagnosis of hypoestrogenism along with symptoms of delayed puberty. Information was taken from medical records who visited the clinic between 2020 and 2023. A BMI-for-age percentile calculation was made using CDC growth charts as a guide. Three groups comprised us: The first group, consisting of fifty-five patients, underwent lifestyle modification, A second group of fifty-five individuals received aromatase inhibitors in conjunction with lifestyle modification, Third Group: fifty-five patients where used Life style modifation with Placebo. Findings: We examined 165 boys’ medical records. In 2021, out of the 35 patients that underwent evaluation, 34% were overweight, 54% were obese, and 12% had severe obesity. In 2022, out of the 54 individuals that underwent evaluation, 35% were overweight, 43% were obese, and 22% had severe obesity. As of 2023, out of the 76 patients that underwent evaluation, 31% were overweight, 46% were obese, and 23 severely obese. Following a half-year of therapy, the II group experienced a statistically significant rise in testosterone and a statistically significant drop in estradiol. The same outcomes were observed for HOMA-IR, metabolic indices, and pubertal development.

Conclusions: Recent research indicates that the prevalence of obesity and the metabolic syndrome is correlated with the increase in hypoestrogenic, hypogonadotropic teenagers. Aromatase inhibitors are more beneficial when used in this type of patient, although more controlled research is required to confirm the safety and effectiveness of aromatase inhibitors in juvenile patients.